HUMAN CANCER BIOLOGY

2164 Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL
Naoko Kanemitsu, Yasushi Isobe, Azuchi Masuda, Shuji Momose, Morihiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, and Norio Komatsu

2173 Loss of Transforming Growth Factor Beta Type II Receptor Increases Aggressive Tumor Behavior and Reduces Survival in Lung Adenocarcinaoma and Squamous Cell Carcinoma

CANCER THERAPY: PRECLINICAL

2184 RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors

2199 Stem-like Tumor-Initiating Cells Isolated from IL13Ra2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T Cells
Christine E. Brown, Renate Starr, Brenda Aguilar, Andrew F. Shami, Catalina Martinez, Massimo D’Apuzzo, Michael E. Barish, Stephen J. Forman, and Michael C. Jensen

2210 Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
Daruka Mahadevan, Amy Stejskal, Laurence S. Cooke, Ann Munziello, Carla Morales, Daniel O. Persky, Richard I. Fisher, Thomas P. Miller, and Wenhong Qi
First Evidence That \( \gamma \)-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-\( \kappa \)B Pathway

Kanjoormana A. Manu, Muthu K. Shanmugam, Lalitha Ramachandra, Feng Li, Chee Wui Fong, Alan Prem Kumar, Patrick Tan, and Gautam Sethi

The HDAC Inhibitor LBH589 Enhances the Anti-myeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin

Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Eline Menu, Els Van Valkenborgh, Elke De Bryune, Anders Osterborg, Peter Atadja, Olle Larsson, Magnus Axelsson, Ben Van Camp, Helena Jernberg-Wiklund, and Karin Vanderkerken

Improved Efficacy of Dendritic Cell–Based Immunotherapy by Cutaneous Laser Illumination

Xinyuan Chen, Qiyan Zeng, and Mei X. Wu

Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas

Kan Zhai, Xianbo Tian, Chen Wu, Ning Lu, Jiang Chang, Liming Huang, Tongwen Zhang, Yuling Zhou, Yan Qiao, Dianke Yu, Wen Tan, Jieping Chen, and Dongxin Lin

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review

Xiaoyun Liao, Teppie Morikawa, Paul Lochhead, Yo Imamura, Aya Kuchiba, Mai Yamauchi, Katsuhiko Nosho, Zhi Rong Qian, Reiko Nishihara, Jeffrey A. Meyerhardt, Charles S. Fuchs, and Shuji Ogino

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes

Kanwal P. Raghu, Wenting Wang, Shuying Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. Blumenschein Jr, and Ana M. Gonzalez-Angulo

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma


Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

Josep M. Llovet, Carol E.A. Peña, Chetan D. Lathia, Michael Shan, Gerold Meinhardt, and Jordi Bruix on behalf of the SHARP Investigators Study Group

The Use and Interpretation of Competing Risks Regression Models

James J. Dignam, Qiang Zhang, and Masha Kocherginsky

Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

Manish R. Sharma, Theodore G. Karrison, Yuyan Jin, Robert B. Bies, Michael L. Maitland, Walter M. Stadler, and Mark J. Ratain

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer


BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency

David S. Hong, Luis Vence, Gerald Falchook, Laszlo G. Radavanyi, Chengwen Liu, Vicki Goodman, Jefery J. Legos, Sam Blackman, Antonio Scarmadillo, Razelle Kurzrock, Gregory Lizée, and Patrick Hwu
ABOUT THE COVER

RAF265 greatly reduces the activation of MEK1 in melanoma patient tumors. Photomicrograph showing immunohistochemical localization of a remaining low level of active phospho-MEK1 (green) in a melanoma patient tumor that was treated with RAF265 after being implanted into a nude mouse. Nuclei are stained with DAPI and appear blue. 20X magnification. For details, see the article by Su and colleagues on page 2184 of this issue.